ABPI director to step down in light of new UK re-imbursement negotiations
This article was originally published in SRA
Richard Barker, the director general of the UK R&D industry association, the ABPI, is to step down in May 2011 after six years in the post, to let a successor take over the lengthy negotiations that are expected with the coalition government when it introduces value-based pricing (VBP) to replace the Pharmaceutical Price Regulation Scheme (PPRS) in 20141. The search for a successor will begin immediately, with the aim of making an appointment in spring 2011.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.